1. Home
  2. TRIN vs TRVI Comparison

TRIN vs TRVI Comparison

Compare TRIN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRIN

Trinity Capital Inc.

HOLD

Current Price

$16.80

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$14.82

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIN
TRVI
Founded
2007
2011
Country
United States
United States
Employees
109
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
TRIN
TRVI
Price
$16.80
$14.82
Analyst Decision
Buy
Strong Buy
Analyst Count
5
11
Target Price
$16.00
$21.55
AVG Volume (30 Days)
1.2M
1.8M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
12.61%
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.41
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
$7.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.76
$5.38
52 Week High
$17.38
$16.12

Technical Indicators

Market Signals
Indicator
TRIN
TRVI
Relative Strength Index (RSI) 63.13 62.48
Support Level $14.31 $10.07
Resistance Level $17.20 $16.12
Average True Range (ATR) 0.34 0.76
MACD 0.05 -0.06
Stochastic Oscillator 67.57 78.12

Price Performance

Historical Comparison
TRIN
TRVI

About TRIN Trinity Capital Inc.

Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: